Track topics on Twitter Track topics that are important to you
TOT BIOPHARM of Suzhou broke ground on Phase II of its production facility in Suzhou Industrial Park. The addition, which will comprise 140,000 square feet of floor space, will be dedicated to biologic drugs, including biosimilars, monoclonal antibody drugs and antibody-drug conjugates. The facility's Phase I construction was completed in 2012 and devoted to small-molecule cancer drugs. TOT, founded in 2010, develops difficult-to-make drugs and affordable cancer products aimed at China's needs. More details....
Share this with colleagues:
Original Article: TOT Breaks Ground on Biologics Production Facility in SuzhouNEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...